MyOme
PrivateLast Round
VC Round
Dec 11, 2025
Est. Valuation
$132M
Total Funding Raised
$36.4M
Company Overview
MyOme operates in Healthcare & Life Sciences and is based in Menlo Park, California. Its latest recorded funding round was a VC Round in December 2025.
MyOme is a biotechnology company that offers gene analytics technology to assess the impact of DNA on health and well-being through genome sequencing, helping families understand and mitigate the risk of hereditary diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, Medical AI
Business Model
B2B2C
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MyOme Comparables
Compare MyOme with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Variantyx | 79% | |
| Nucleus Genomics | 79% | |
| Genomic Prediction | 70% |
For institutional investors. Book with your work email.
MyOme Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 11, 2025 | ||||
| Series B | Jun 21, 2022 | ||||
| Series A | Oct 23, 2019 | ||||
| Seed | Jul 17, 2019 |
For institutional investors. Book with your work email.
MyOme Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Founders Fund | Series B |
| SoftBank Group | Series B |
| Norwest Venture Partners | Series A, Series B, Seed |
| Sequoia Capital | Series B, VC Round |
| Foresite Capital | Series B |
| SoftBank Corp | Series B |
| HOF Capital | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Dr. Ravi Thadhani joins the Board of Directors.
- Apr 21, 2026
Sam Roosz appointed to the Board of Directors.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 4, 2026
MyOme, Inc. and SickKids co collaborate in California on Nov 4th '26 under a licensing and research agreement to integrate SickKids-developed DNA methylation signatures into clinical rare disease testing and validate them using long-read sequencing.
For institutional investors. Book with your work email.
MyOme Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MyOme's valuation, stock price, and market status.
Is MyOme a public or private company?
MyOme is a private company.
What is the current stock price of MyOme?
MyOme is a private company, so its shares have no public market price. Caplight tracks MyOme's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MyOme worth (valuation)?
MyOme's valuation is estimated at $132.0M based on funding round data.
Can I buy MyOme stock?
MyOme shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MyOme's last funding round?
MyOme's most recent funding round was VC Round on December 11, 2025.
Who are the main investors in MyOme?
Key investors in MyOme include Norwest Venture Partners, Healthcare Venture Partners.
Will MyOme IPO soon?
No public IPO plans have been announced for MyOme.
How can I track MyOme secondary market activity?
Caplight tracks bids, offers, and trades in MyOme's shares on secondary markets.